FDA Approves New Drug for Depression Called Esketamine; Chemical Cousin to Illegal Club Drug “Special K”, Otherwise Known as Ketamine


NEW YORK – The Food and Drug Administration (FDA) approved esketamine nasal spray Tuesday to treat people with depression who have not found relief with traditional antidepressants.

“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” Dr. Tiffany Farchione of the FDA’s Center for Drug Evaluation and Research said in a statement.

The drug will be manufactured by Janssen, a subsidiary of Johnson & Johnson, and sold as Spravato, reported BBC. Janssen said the spray can help adults dealing with depression and suicidal thoughts within 24 hours. The drug works by targeting glutamate, a chemical that is essential for normal brain function.

Patients cannot administer the spray at home. They must be supervised at a doctor’s office or clinic for two hours every time they take Spravato because of its side effects including dissociation, suicidal thoughts and a sense of detachment from one’s identity, according to the FDA.

Spravato is intended to be taken alongside an oral antidepressants, reported BBC.


Big Tech is using a content filtering system for online censorship. Watch our short video about NewsGuard to learn how they control the narrative for the Lamestream Media and help keep you in the dark. NewsGuard works with Big-Tech to make it harder for you to find certain content they feel is 'missing context' or stories their editors deem "not in your best interest" - regardless of whether they are true and/or factually accurate. They also work with payment processors and ad-networks to cut off revenue streams to publications they rate poorly by their same bias standards. This should be criminal in America. You can bypass this third-world nonsense by signing up for featured stories by email and get the good stuff delivered right to your inbox.

The esketamine nasal spray’s wholesale price per treatment will be between $590 and $885, Johnson & Johnson said according to NPR. Jennifer Taubert, worldwide chairwoman of pharmaceuticals for Johnson & Johnson, was one of seven pharmaceutical company executives who testified at a Senate Finance Committee hearing on drug prices on Feb. 26.

Some experts maintain esketamine is not ready to hit the market.

“The threshold has been two adequate and well-controlled trials. In this case, they only got one,” Dr. Erick Turner, a former FDA reviewer and professor at Oregon Health and Science University, said according to BBC.

An FDA advisory panel made waves when it approved esketamine for depression in February.

Follow Evie on Twitter @eviefordham.

Get great news content like this for your business website. Search engines love sites with frequently updated quality content and reward them with better search rankings. Get High Quality Content Updates for your site.
Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to corrections@publishedreporter.com and cite any sources if available. Thank you. (Policy)